Spero Therapeutics (SPRO) reported a net loss of $44.3 million, or $0.76 per diluted share, for the third quarter ended September 30, 2026. The company reported no revenue in the quarter.
Spero ended the quarter with $107.9 million in cash and cash equivalents and said the balance is expected to fund operations into the second half of 2029. The company plans to initiate a Phase 2 study of SP001 in IgG4-related disease in the second quarter of 2027.
- Third-quarter research and development expense was $38.2 million, compared with $8.6 million a year earlier.
- General and administrative expense was $3.7 million, compared with $4.2 million in the prior-year quarter.
- In July 2026, Spero closed a $105 million non-recourse, non-dilutive milestone and royalty financing with affiliates of HealthCare Royalty Partners.
- Spero in-licensed SP001 from Innovent Biologics in July 2026, obtaining exclusive worldwide rights outside Greater China.
$SPRO Insider Trading Activity
$SPRO insiders have traded $SPRO stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $SPRO stock by insiders over the last 6 months:
- ESTHER RAJAVELU (See Remarks) sold 40,851 shares for an estimated $42,485
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$SPRO Hedge Fund Activity
We have seen 38 institutional investors add shares of $SPRO stock to their portfolio, and 26 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MACKENZIE FINANCIAL CORP added 1,831,254 shares (+inf%) to their portfolio in Q3 2026, for an estimated $2,215,817
- ALPHABET INC. removed 889,979 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $1,076,874
- TWO SIGMA INVESTMENTS, LP removed 502,817 shares (-56.8%) from their portfolio in Q2 2026, for an estimated $1,111,225
- RENAISSANCE TECHNOLOGIES LLC added 461,879 shares (+48.7%) to their portfolio in Q3 2026, for an estimated $558,873
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 426,175 shares (+127.9%) to their portfolio in Q2 2026, for an estimated $941,846
- ANSON FUNDS MANAGEMENT LP removed 421,956 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $932,522
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 332,970 shares (+inf%) to their portfolio in Q2 2026, for an estimated $735,863
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
